Chimerix Announces Final Data from AdVise Trial of Brincidofovir at BMT Tandem Meetings Pharmaceutical Investing
Immune Design Receives Orphan Drug Designation for G100 Intratumoral Product Candidate Pharmaceutical Investing
Alimera Sciences and Knight Therapeutics Announce Filing of New Drug Submission for Iluvien® in Canada Pharmaceutical Investing
VBI Vaccines Receives Positive Response from Health Canada's Initial Evaluation of the Proposed Sci-B-Vac Phase III Clinical Program Pharmaceutical Investing
OncoGenex Pharmaceuticals Announce Phase 2 Apatorsen Data from Two Clinical Trials Pharmaceutical Investing
Takeda and TiGenix Report New Data Highlighting Maintenance of Long-Term Remission of Complex Perianal Fistulas in Crohn's Disease Patients with Cx601 Pharmaceutical Investing
Adamas to Present New ADS-5102 Data from Phase 2 Trial in Walking Impairment Associated with Multiple Sclerosis Pharmaceutical Investing
Momenta Pharmaceuticals Announces HSR Clearance for Collaboration and License Agreement with CSL Pharmaceutical Investing
Immune Pharmaceuticals Announces the launch of REMAIN ™ , an international Overall Survival study with Ceplene® and low dose Proleukin® in REmission MAINtenance in Acute Myeloid Leukemia Pharmaceutical Investing
Clearside Biomedical Announces First Patient Randomized in Phase 3 Clinical Trial of Zuprata™ Used Together With Eylea in Subjects With Retinal Vein Occlusion Pharmaceutical Investing
